⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82576 | 1.00 | — | — | |
| SCHEMBL26616730 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL5004514 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL31381872 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL29714886 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL4780528 | 0.97 | — | — | |
| SCHEMBL518569 | 0.95 | GABRA5 (0.35) | — | |
| SCHEMBL568788 | 0.87 | — | — | |
| SCHEMBL3679491 | 0.84 | — | — | |
| SCHEMBL18732892 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626892-A1 | ADENOSINE A2A AND A2B RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | Merck Sharp & Dohme LLC (US) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025134078-A1 | ORGANIC COMPOUNDS AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMS) | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-06-26 | — | — | WO | disclosed |
| CN-119330972-A | PARP7 inhibitor and application thereof | 重庆华森英诺生物科技有限公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2024118460-A1 | ADENOSINE A2A AND A2B RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-06-06 | — | — | WO | disclosed |
| EP-3253752-B1 | [9,10-DIMETHOXY-3-(2-METHYLPROPYL)-1H,2H,3H,4H,6H,7H,11BH-PYRIDO-[2,1-A]ISOQUINOLIN-2-YL]METHANOL AND COMPOUNDS, COMPOSITIONS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022152274-A1 | FGFR INHIBITOR COMPOUND AND USE THEREOF | 深圳康溯医药科技有限公司 | 2022-07-21 | — | — | WO | disclosed |
| CN-114727991-A | Arylmethylene heterocyclic compounds as Kv1.3 potassium SHAKER channel blockers | D·E·萧尔研究有限责任公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114524818-A | FGFR inhibitor compounds and uses thereof | 深圳康溯医药科技有限公司 | 2022-05-24 | — | — | CN | disclosed |
| CN-107592861-A | It is fluorinated inhibitor of lysyloxidase sample 2 and application thereof | 法玛克亚公司 | 2018-01-16 | — | — | CN | disclosed |
| WO-2016014982-A1 | N-METHYL-D-ASPARTATE RECEPTOR MODULATORS AND METHODS OF MAKING AND USING SAME | NAUREX, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
| WO-2013090836-A1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-06-20 | — | — | WO | disclosed |
| US-20070129364-A1 | Pyrrolopyridine kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | disclosed |